The NASDAQ OMX Group, Inc. (Nasdaq:NDAQ) and Chaikin Analytics, LLC announced the launch of three NASDAQ Chaikin Power Indexes: the NASDAQ Chaikin Power US Large Cap Index(SM) (NQULCHK), the NASDAQ Chaikin Power US Small Cap Index(SM) (NQUSCHK), and the NASDAQ Chaikin Power US Dividend Achievers Index(SM) (NQDACHK). These new indexes are rules-based, quantitatively enabled investment strategies, designed to outperform their respective benchmarks and are based on the Chaikin Power Gauge, a multi-factor quantitative model. NASDAQ OMX Group, Inc. (NASDAQ:NDAQ) stock opened today at $37.10 and is currently trading at $37.24. The stock showed a positive weekly performance of -1.65%.
Trade-Ideas LLC identified Ctrip.com International (NASDQ:CTRP) as a pre-market leader candidate. In addition to specific proprietary factors, Trade-Ideas identified Ctrip.com International as such a stock due to the following factors: CTRP has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $180.3 million.Ctrip.com International, Ltd. (ADR) (NASDAQ:CTRP) stock opened at $53.91, in current trading session and currently is at $53.06, by gaining 1.71%.The 52 week range of $18.87-$61.09. Company’s market capitalization is $6.91 billion.
Acacia Research Corporation (Nasdaq: ACTG) announced that its Bonutti Skeletal Innovations LLC subsidiary has entered into a settlement and patent license agreement with Biomet, Inc., Biomet Sports Medicine, LLC, Biomet Manufacturing, LLC (formerly doing business as Biomet Manufacturing Corp.) The agreement resolves litigation pertaining to suture anchors and platelet concentration that was pending in the United States District Court for the Northern District of Indiana. Acacia Research Corp (NASDAQ:ACTG) stock is currently trading at $17.50 .The EPS of the stock is -0.28. Company’s market capitalization is $886.20 million.
Gilead Sciences, Inc. (Nasdaq:GILD) announced topline results from a Phase 3 clinical trial (Study GS-US-334-0118) in Japan evaluating the once-daily nucleotide analog polymerase inhibitor sofosbuvir in combination with ribavirin (RBV) for the treatment of genotype 2 chronic hepatitis C virus (HCV) infection. The study met its primary efficacy endpoint of superiority compared to a predefined historical control sustained virologic response (SVR) rate. In the study, 97 percent (n=148/153) of genotype 2 HCV-infected patients receiving 12 weeks of an all-oral regimen of sofosbuvir plus RBV achieved a sustained virologic response 12 weeks after completing therapy (SVR12). SVR12 rates among treatment-naïve and treatment-experienced patients were 98 percent (n=88/90) and 95 percent (n=60/63), respectively. Of the 153 patients who received treatment, 11 percent (n=17) had documented cirrhosis. Gilead Sciences, Inc. (NASDAQ:GILD) stock opened the session at $75.18, and now is at $74.15. The 52 week range of the GILD stock remained $46.53-$84.88 and the day range was $73.94-$75.18.